Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

D-915

Supelco

Desalkylflurazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C15H10ClFN2O
Número de CAS:
2886-65-9
Peso molecular:
288.70
Número CE:
200-659-6
Número MDL:
MFCD00083443
Código UNSPSC:
41116107
NACRES:
NA.24

grado

certified reference material

Formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

concentración

1.0 mg/mL in methanol

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

Formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

Clave InChI

UVCOILFBWYKHHB-UHFFFAOYSA-N

Descripción general

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Producto relacionado

Referencia del producto
Descripción
Precios

D-924

Desalkylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-003

Flurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-901

2-Hydroxyethylflurazepam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-902

2-Hydroxyethylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-919

2-Hydroxyethylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-923

2-Hydroxyethylflurazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órganos de actuación

Eyes,Central nervous system

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

49.5 °F - closed cup

Punto de inflamabilidad (°C)

9.7 °C - closed cup

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

K Schaffler et al.
Arzneimittel-Forschung, 39(2), 276-283 (1989-02-01)
To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers. The design covered a 1-week placebo run-in period, a period with daily oral night-time administration of
J M Hilbert et al.
Clinical pharmacology and therapeutics, 36(4), 566-569 (1984-10-01)
The kinetics of quazepam, a benzodiazepine hypnotic, was studied in 10 geriatric subjects. Each received one 15-mg tablet of quazepam. Blood samples were collected before and at specified times (up to 672 hr) after dosing. Plasma concentrations of quazepam and
S Ueki et al.
Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 82(5), 395-409 (1983-11-01)
The behavioral effects of ethyl loflazepate and its metabolites were investigated in mice and rats, and they were compared with those of diazepam, nitrazepam and lorazepam. Locomotor activity of rats in open-field situation was increased with a wide range of
S K Gupta et al.
Pharmaceutical research, 5(6), 365-368 (1988-06-01)
A reverse-phase liquid chromatographic method is described for simultaneous quantification of quazepam, and two of its metabolites, 2-oxoquazepam and N-desaklyl-2-oxoquazepam. The method uses a solid-phase extraction procedure to prepare plasma samples. After extraction, the methanolic extract is evaporated; the residue
Y Sakai et al.
Japanese journal of pharmacology, 37(4), 373-379 (1985-04-01)
A new benzodiazepine compound, ethyl loflazepate (ethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H,1,4- benzodiazepine-3-carboxylate; CM6912) was studied using in vitro experimental systems for its displacement activity on 3H-diazepam binding to the synaptosomal membrane fraction of rat cerebrum and potentiating action on GABA. CM6912 inhibited the specific
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico